Ameritas Advisory Services LLC Sells 7,472 Shares of Novo Nordisk A/S (NYSE:NVO)

Ameritas Advisory Services LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 67.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,528 shares of the company's stock after selling 7,472 shares during the quarter. Ameritas Advisory Services LLC's holdings in Novo Nordisk A/S were worth $245,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Victory Capital Management Inc. grew its stake in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after acquiring an additional 23,223 shares in the last quarter. North Star Investment Management Corp. boosted its holdings in Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock worth $1,440,000 after purchasing an additional 3,200 shares during the last quarter. Stanley Laman Group Ltd. bought a new stake in Novo Nordisk A/S in the 1st quarter worth about $390,000. Dover Advisors LLC bought a new stake in Novo Nordisk A/S in the 1st quarter worth about $505,000. Finally, Natural Investments LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at about $1,345,000. 11.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NVO. Hsbc Global Res upgraded Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, BMO Capital Markets reissued a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Hold" and an average target price of $112.00.

Novo Nordisk A/S Stock Down 1.1%

Shares of NYSE NVO opened at $69.05 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The stock has a market capitalization of $308.31 billion, a PE ratio of 20.43, a P/E/G ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $143.69. The business's fifty day moving average price is $69.82 and its 200-day moving average price is $76.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.